Reported 1 day ago
Piper Sandler has initiated coverage of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) with an Overweight rating and a price target of $25. The firm acknowledges recent declines in stock prices following the company’s earnings reports, attributing it to concerns over the performance plateau of the cancer drug OJEMDA (tovorafenib). Despite the initial slowdown in growth, Piper Sandler believes that the drug's strong clinical data will facilitate long-term market success for Day One Biopharmaceuticals.
Source: YAHOO